Healthcare | March 20, 2024
Aster’s India and GCC business separation nearing completion
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
A five-day inspection was concluded successfully with no critical and no major observations raised
Additional capacity broadens Grace’s fine chemical capabilities for API production
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Both organisations enter into a long- term collaboration to expand patient access in India
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
More than 10,000 scientific publications containing EUDRAGIT
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Subscribe To Our Newsletter & Stay Updated
